Stock Scorecard

Stock Summary for Adverum Biotechnologies Inc (ADVM) - $4.12 as of 11/28/2025 8:41:14 PM EST

Total Score

7 out of 30

Safety Score

21 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ADVM

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ADVM

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ADVM

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ADVM

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ADVM (21 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 6
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ADVM

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM 10/25/2025 12:00:00 AM
Adverum Biotechnologies Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo 10/16/2025 10:39:00 AM
After losing 28% in the past year, Adverum Biotechnologies, Inc. (NASDAQ:ADVM) institutional owners must be relieved by the recent gain 10/3/2025 12:00:00 AM
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration 9/22/2025 8:00:00 AM
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights 8/12/2025 7:00:00 AM
Adverum biotechnologies sees $147k stock purchase by major shareholder 4/2/2025 6:09:00 PM
Adverum Biotechnologies raises $127.5 million for gene therapy pipeline 12/31/2024 11:59:00 PM
LUNA, OPTIC Data Support Long-Term Benefit of Ixo-Vec for Wet AMD 11/24/2024 12:00:00 AM
Adverum Biotechnologies announces FDA Regenerative Medicine Advanced Therapy designation granted for Ixo-vec for treatment of wet AMD 8/2/2024 12:00:00 AM
Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference 8/14/2023 8:00:00 AM

Financial Details for ADVM

Company Overview
Ticker ADVM
Company Name Adverum Biotechnologies Inc
Country USA
Description Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company headquartered in Redwood City, California, dedicated to developing transformative therapeutic solutions for rare diseases and ophthalmic disorders. The company boasts a promising pipeline of gene therapy candidates that harness its proprietary adeno-associated virus (AAV) technologies, aiming to meet substantial unmet medical needs. By focusing on innovative treatments, Adverum is strategically positioned to enhance patient outcomes and solidify its presence within the rapidly advancing gene therapy landscape.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 4.12
Price 4 Years Ago 17.60
Last Day Price Updated 11/28/2025 8:41:14 PM EST
Last Day Volume 103,394
Average Daily Volume 809,045
52-Week High 6.98
52-Week Low 1.78
Last Price to 52 Week Low 131.46%

Valuation Measures
Trailing PE N/A
Industry PE 43.72
Sector PE 89.93
5-Year Average PE -3.90
Free Cash Flow Ratio 3.49
Industry Free Cash Flow Ratio 14.11
Sector Free Cash Flow Ratio 29.09
Current Ratio Most Recent Quarter 0.65
Total Cash Per Share 1.18
Book Value Per Share Most Recent Quarter -2.53
Price to Book Ratio 0.93
Industry Price to Book Ratio 33.64
Sector Price to Book Ratio 33.13
Price to Sales Ratio Twelve Trailing Months 94.37
Industry Price to Sales Ratio Twelve Trailing Months 32.13
Sector Price to Sales Ratio Twelve Trailing Months 16.04
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 1

Share Statistics
Total Shares Outstanding 22,077,500
Market Capitalization 90,959,300
Institutional Ownership 64.00%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -7.22%
Reported EPS 12 Trailing Months -8.56
Reported EPS Past Year -6.33
Reported EPS Prior Year -5.65
Net Income Twelve Trailing Months -204,392,000
Net Income Past Year -130,927,000
Net Income Prior Year -122,116,000
Quarterly Revenue Growth YOY -70.00%
5-Year Revenue Growth 31.95%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 26,060,000
Total Cash Past Year 60,652,000
Total Cash Prior Year 75,000,000
Net Cash Position Most Recent Quarter 26,060,000
Net Cash Position Past Year 60,652,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 100,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 0.00
Total Stockholder Equity Past Year 70,714,000
Total Stockholder Equity Prior Year 67,222,000
Total Stockholder Equity Most Recent Quarter -55,653,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -138,445,000
Free Cash Flow Per Share Twelve Trailing Months -6.27
Free Cash Flow Past Year -92,850,000
Free Cash Flow Prior Year -91,710,000

Options
Put/Call Ratio 5.45
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.04
MACD Signal -0.02
20-Day Bollinger Lower Band 1.97
20-Day Bollinger Middle Band 3.68
20-Day Bollinger Upper Band 5.39
Beta 0.87
RSI 41.74
50-Day SMA 3.68
150-Day SMA 8.25
200-Day SMA 8.94

System
Modified 11/28/2025 4:33:53 PM EST